Share on

Middle East & Africa Non-Invasive Cancer Diagnostics Market Research Report - Segmented By Therapeutics, Techniques & Country (KSA, UAE, Israel, rest of GCC countries, South Africa, Ethiopia, Kenya, Egypt, Sudan, rest of MEA) - Industry Analysis on Size, Share, Trends, Growth, Forecast | 2023 to 2028

Published: March, 2023
ID: 5373
Pages: 145
Formats: report pdf report excel report power bi report ppt

Middle East & Africa Non-Invasive Cancer Diagnostics Market Size & Growth (2023 to 2028)

According to the report, the MEA Non-Invasive Cancer Diagnostics Market Size is valued at USD 7.07 billion in 2023 and predicted to grow at a CAGR of 5.48%, reaching USD 9.23 billion by the end of 2028 during the forecast period 2023 to 2028.

Factors such as the increasing incidence of various types of cancer need for better diagnostics procedures, and the growing target population will drive the MEA non-invasive cancer diagnostics market over the forecast period. According to the WHO and the World Cancer Report, the new cancer cases were reported to be around 15 million per year, with breast, ovarian and gastrointestinal cancers projected to be the most common types.

Additionally, increasing technological advancements focusing on better analysis of cancer cells, improving kits to identify the type of cancer, and improving the efficiency of the result will help the market grow. Currently, molecular diagnostic methods are becoming increasingly very popular among physicians due to new detection methods based on biomarkers and following-generation sequencing techniques.

An increase in government and private organizations' initiatives to create awareness for early diagnosis and prevention of cancer coupled with a growing number of diagnostic laboratories is projected to drive the market in the coming years. Early cancer detection has been associated with a greater survival rate among many cancer types.

According to the World Health Organization (WHO) report, cancer is the second leading cause of death, accounting for more than 9.65 million deaths in 2018, with one in six deaths being cancer. A sharp increase in the emphasis on health and prevention with yoga and other health-related practices will provide an opportunity for growth during the forecast period.

Governmental and non-governmental organizations are focusing on raising awareness of cervical and breast cancer and carrying out screening programs to improve diagnosis rates and help drug development.

However, the vast costs associated with the diagnostic imaging system and the development of different diagnostic approaches for various cancers may hamper the market growth. Moreover, developing and untapped economic markets are reluctant to adopt these expensive procedures, which will create a challenge for the MEA non-invasive cancer diagnostics market.

This research report on the Middle East & Africa Non-Invasive Cancer Diagnostics Market has been segmented and sub-segmented into the following categories.

By Therapeutics: 

  • Blood cancer
  • Breast Cancer
  • Lung Cancer
  • Solid tumors

By Techniques:

  • Immunochemistry
  • Clinical Chemistry
  • Molecular Diagnostics

By Country:

  • KSA
  • UAE
  • Israel
  • the rest of GCC countries
  • South Africa
  • Ethiopia
  • Kenya
  • Egypt
  • Sudan
  • rest of MEA

Geographically, the Middle East & Africa Non-Invasive Cancer Diagnostics Market accounted for the largest market share globally due to the growing prevalence of cancer in the elderly population during the forecast period.

The UAE Non-Invasive Cancer Diagnostics Market is predicted to reach a decent CAGR due to technological advancements and improved reimbursement scenarios. In addition, government initiatives in the early detection of cancer will be responsible for driving the market over the predicted period.

The Saudi Arabia Non-Invasive Cancer Diagnostics Market is expected to hold the dominant position during the analysis period owing to the factors such as improving health spending and support reimbursement policies during the forecasted period.

The South African Non-Invasive Cancer Diagnostics Market is likely to be highly lucrative and is projected to reach the highest CAGR due to the increased government cancer awareness programs and product launches for effective healthcare diagnosis.

KEY MARKET PLAYERS

Key Market Companies dominating the Middle East & Africa Non-Invasive Cancer Diagnostics Market Profiled in the Report are Precision Therapeutics, Affymetrix Inc., AVIVA Biosciences Corporation, A&G Pharmaceutical, Quest Diagnostics Incorporated, Cancer Genetics Inc., Laboratory Corporation of America Holdings (LabCorp), BIOVIEW Inc., Digene Corporation and Gen-Probe Incorporated.,

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: [email protected]

Click for Request Sample